Drug General Information |
Drug ID |
D06BVH
|
Former ID |
DNC007739
|
Drug Name |
4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C17H12N4
|
Canonical SMILES |
C1=CC=C(C=C1)C2=NC(=NC=C2C#N)NC3=CC=CC=C3
|
InChI |
1S/C17H12N4/c18-11-14-12-19-17(20-15-9-5-2-6-10-15)21-16(14)13-7-3-1-4-8-13/h1-10,12H,(H,19,20,21)
|
InChIKey |
KLNVGLIZGCKXCE-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Vascular endothelial growth factor receptor 2 |
Target Info |
Inhibitor |
[1]
|
Cell division control protein 2 homolog |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
Cytokine-cytokine receptor interaction
|
Endocytosis
|
PI3K-Akt signaling pathway
|
VEGF signaling pathway
|
Focal adhesion
|
Proteoglycans in cancerhsa04110:Cell cycle
|
Oocyte meiosis
|
p53 signaling pathway
|
Gap junction
|
Progesterone-mediated oocyte maturation
|
Herpes simplex infection
|
Epstein-Barr virus infection
|
Viral carcinogenesis
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_21:RANKL Signaling Pathway
|
PANTHER Pathway
|
Angiogenesis
|
VEGF signaling pathway
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
Beta3 integrin cell surface interactions
|
Signaling events mediated by TCPTP
|
SHP2 signaling
|
S1P1 pathway
|
VEGF and VEGFR signaling network
|
Integrins in angiogenesis
|
Signaling events mediated by VEGFR1 and VEGFR2
|
Notch-mediated HES/HEY networkp73pathway:p73 transcription factor network
|
E2F transcription factor network
|
PLK1 signaling events
|
AP-1 transcription factor network
|
FOXM1 transcription factor network
|
Retinoic acid receptors-mediated signaling
|
Reactome
|
Neurophilin interactions with VEGF and VEGFR
|
VEGF binds to VEGFR leading to receptor dimerization
|
Integrin cell surface interactions
|
EPHA-mediated growth cone collapse
|
VEGFA-VEGFR2 Pathway
|
VEGFR2 mediated cell proliferationR-HSA-110056:MAPK3 (ERK1) activation
|
E2F mediated regulation of DNA replication
|
G0 and Early G1
|
Cyclin B2 mediated events
|
Golgi Cisternae Pericentriolar Stack Reorganization
|
Cdc20:Phospho-APC/C mediated degradation of Cyclin A
|
Regulation of APC/C activators between G1/S and early anaphase
|
Phosphorylation of the APC/C
|
Phosphorylation of Emi1
|
Condensation of Prophase Chromosomes
|
MASTL Facilitates Mitotic Progression
|
Resolution of Sister Chromatid Cohesion
|
Condensation of Prometaphase Chromosomes
|
Regulation of PLK1 Activity at G2/M Transition
|
Activation of NIMA Kinases NEK9, NEK6, NEK7
|
Loss of Nlp from mitotic centrosomes
|
Recruitment of mitotic centrosome proteins and complexes
|
Loss of proteins required for interphase microtubule organization?from the centrosome
|
Recruitment of NuMA to mitotic centrosomes
|
Depolymerisation of the Nuclear Lamina
|
Anchoring of the basal body to the plasma membrane
|
MAPK6/MAPK4 signaling
|
G1/S-Specific Transcription
|
Cyclin A/B1 associated events during G2/M transition
|
G2/M DNA replication checkpoint
|
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
|
WikiPathways
|
Focal Adhesion
|
Nifedipine Activity
|
Cardiac Progenitor Differentiation
|
Signaling by VEGF
|
AngiogenesisWP707:DNA Damage Response
|
G1 to S cell cycle control
|
TGF beta Signaling Pathway
|
PPAR Alpha Pathway
|
MAP kinase activation in TLR cascade
|
RAF/MAP kinase cascade
|
Mitotic Prophase
|
Mitotic Prometaphase
|
BMI1
|
ATM Signaling Pathway
|
Retinoblastoma (RB) in Cancer
|
Spinal Cord Injury
|
Prostate Cancer
|
Regulation of Microtubule Cytoskeleton
|
Integrated Cancer pathway
|
Mitotic G2-G2/M phases
|
Mitotic G1-G1/S phases
|
Cell Cycle
|
APC/C-mediated degradation of cell cycle proteins
|
Cell Cycle Checkpoints
|
miRNA Regulation of DNA Damage Response
|
References |
REF 1 | Bioorg Med Chem Lett. 2007 Jun 15;17(12):3266-70. Epub 2007 Apr 10.4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation. |